Arvinas, Inc. (ARVN)
| Market Cap | 468.17M -32.2% |
| Revenue (ttm) | 316.70M -15.0% |
| Net Income | 9.30M |
| EPS | 0.13 |
| Shares Out | 65.39M |
| PE Ratio | 53.56 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 604,841 |
| Open | 6.88 |
| Previous Close | 6.82 |
| Day's Range | 6.83 - 7.18 |
| 52-Week Range | 6.74 - 14.51 |
| Beta | 1.81 |
| Analysts | Buy |
| Price Target | 13.93 (+94.55%) |
| Est. Earnings | Nov 4, 2026 |
About ARVN
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs, including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such... [Read more]
Financial Performance
In 2025, Arvinas's revenue was $262.60 million, a decrease of -0.30% compared to the previous year's $263.40 million. Losses were -$80.80 million, -59.38% less than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for ARVN stock is "Buy." The 12-month stock price target is $13.93, which is an increase of 94.55% from the latest price.
News
Arvinas presents data from clinical trial of ARV-102
Arvinas (ARVN) presented novel data from a Phase 1 clinical trial of ARV-102, an investigational PROteolysis TArgeting Chimera, or PROTAC, degrader designed to specifically target and degrade leucine-...
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease
– Data showed improvements in an objective measure of impaired eye movement associated with Parkinson's disease, with a correlation between reductions in LRRK2 cerebrospinal fluid (CSF) biomarkers to ...
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson's Disease and Movement Disorders®
NEW HAVEN, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno...
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted p...
Arvinas announces first patient dosed in Phase 1/2 trial of ARV-6723
Arvinas (ARVN) announced that the first participant has been dosed in its Phase 1/2 clinical trial of ARV-6723, an investigational, oral PROteolysis TArgeting Chimera, PROTAC, designed to degrade hema...
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate
– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors –
Arvinas Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Leadership is prioritizing early-stage clinical programs, with four phase I assets expected to deliver key data within 18 months. ARV-393, ARV-102, and ARV-027 each target high unmet needs, with strategic flexibility for partnerships and a strong capital position supporting progress.
Arvinas Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Key pipeline programs in oncology and neurology are advancing rapidly, with multiple phase I data readouts expected within the next year. PROTAC degraders show strong scientific rationale and combination potential, while financial resources support continued development through 2028.
Arvinas Transcript: Wells Fargo 21st Annual Healthcare Conference
The discussion highlighted a strategic shift toward advancing a robust clinical pipeline, with key data readouts expected for four programs over the next 15 months. ARV-393 and ARV-102 are nearing pivotal milestones, while SBMA and HPK1 programs are progressing with biomarker-driven strategies. Partnerships and platform expansion remain central to future growth.
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted p...
Arvinas price target lowered to $10 from $11 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Arvinas (ARVN) to $10 from $11 and keeps an Equal Weight rating on the shares.
Arvinas price target lowered to $14 from $19 at Evercore ISI
Evercore ISI lowered the firm’s price target on Arvinas (ARVN) to $14 from $19 and keeps an Outperform rating on the shares.
Arvinas price target lowered to $21 from $24 at Citi
Citi analyst Yigal Nochomovitz lowered the firm’s price target on Arvinas (ARVN) to $21 from $24 and keeps a Buy rating on the shares.
Arvinas price target raised to $12 from $11 at Wedbush
Wedbush analyst Robert Driscoll raised the firm’s price target on Arvinas (ARVN) to $12 from $11 and keeps a Neutral rating on the shares. The firm notes the company reported…
Wells downgrades Arvinas to Equal Weight, sees catalysts coming in 2027
As previously reported, Wells Fargo downgraded Arvinas (ARVN) to Equal Weight from Overweight with a price target of $11, down from $15. While “intrigued” by the company’s early-stage pipeline, the…
Arvinas downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo analyst Derek Archila downgraded Arvinas (ARVN) to Equal Weight from Overweight.
Arvinas reports Q2 EPS $2.58, consensus (28c)
Reports Q2 revenue $249.7M, consensus $60.69M. The revenue increase of $227.3M was primarily due to $112.6M of revenue from the original vepdegestrant collaboration agreement with Pfizer driven by the...
Arvinas Earnings Call Transcript: Q2 2026
Q2 2026 saw FDA approval and out-licensing of VEPPANU, driving $249.7M in revenue and a strong cash position. Focus shifted to phase I oncology and neurology assets, with key data readouts expected in 2026–2027 and a cash runway into 2028.
Arvinas Earnings release: Q2 2026
Arvinas released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Arvinas Quarterly report: Q2 2026
Arvinas has published its Q2 2026 quarterly earnings report on August 4, 2026.
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – – Anticipates s...
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that mana...
Arvinas Transcript: AGM 2026
The meeting was held virtually, with a quorum established and all agenda items—including director elections, executive compensation, and auditor ratification—approved by shareholders. No questions were submitted, and risks related to forward-looking statements were noted.
Arvinas Transcript: Jefferies Global Healthcare Conference 2026
The event highlighted the first approval of a PROTAC degrader, a robust pipeline with multiple phase I programs, and a disciplined strategy prioritizing internal development for high-impact indications like PSP and SBMA. Key milestones include upcoming clinical data for LRRK2, SBMA, and oncology programs.
Arvinas to Present at Jefferies Global Healthcare Conference
NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today annou...